Galectin Therapeutics Inc. (GALT)Healthcare | Biotechnology | Norcross, United States | NasdaqCM
2.45 USD
+0.19
(8.407%)
⇧
(April 17, 2026, 4 p.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 6:39 p.m. EDT
Galectin Therapeutics is a high-risk speculative play with a deteriorating technical trend. Despite positive news headlines and a gap up, the stock is structurally disadvantaged by towering short interest (~27%), deep in-the-money put positioning suggesting a 'glass half full' hedging strategy by bears (or calls to be placed to break even), and a lack of committed bullish call entrapment. The bearish setup at $${<3}$ and the disappointing testing of $${2}$$ resistance make a quick bounce to $${5}$$ unlikely in the immediate term. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.073594 |
| AutoETS | 0.073595 |
| MSTL | 0.075329 |
| AutoTheta | 0.079652 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 4.06 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.008 |
| Excess Kurtosis | 1.31 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 161,277,248 |
| Forward P/E | -1.46 |
| Beta | 1.04 |
| Previous Name | Galectin Therapeutics, Inc. |
| Website | https://galectintherapeutics.com |
As of April 19, 2026, 6:39 p.m. EDT: Options flow indicates high uncertainty and divergent sentiment rather than clear directional bias. Spot OI provides a massive long wall at $${7.50}$$, established to cap downside rather than speculate on an immediate $7+ upside, implying a deep-theta hedge stance. In the very near term ($Apr 17), significant open interest exists on both the $${2.50}$$ ATM and a spike in puts at $${7.50}$$, while insufficient volume exists to determine clear directionality. However, the absence of ITM call OI at $${5.0}$$ and $${7.5}$$ for closer expirations, combined with heavy put volume at $${2.5}$$, suggests speculators are hedging against volatility but not aggressively betting on an immediate move to $${5+}$.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.870229 |
| Address1 | 4,960 Peachtree Industrial Boulevard |
| Address2 | Suite 240 |
| All Time High | 38.28 |
| All Time Low | 0.3 |
| Ask | 2.46 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 412,260 |
| Average Daily Volume3 Month | 323,581 |
| Average Volume | 323,581 |
| Average Volume10Days | 412,260 |
| Beta | 1.037 |
| Bid | 2.4 |
| Bid Size | 1 |
| Book Value | -1.969 |
| City | Norcross |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.45 |
| Current Ratio | 2.42 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.4882 |
| Day Low | 2.29 |
| Display Name | Galectin Therapeutics |
| Earnings Timestamp End | 1,755,261,000 |
| Earnings Timestamp Start | 1,754,915,400 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 283,489,248 |
| Eps Forward | -1.68 |
| Eps Trailing Twelve Months | -0.48 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.8136 |
| Fifty Day Average Change | -0.36360002 |
| Fifty Day Average Change Percent | -0.12922946 |
| Fifty Two Week Change Percent | 87.0229 |
| Fifty Two Week High | 7.13 |
| Fifty Two Week High Change | -4.6800003 |
| Fifty Two Week High Change Percent | -0.65638155 |
| Fifty Two Week Low | 1.21 |
| Fifty Two Week Low Change | 1.24 |
| Fifty Two Week Low Change Percent | 1.0247934 |
| Fifty Two Week Range | 1.21 - 7.13 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,031,146,200,000 |
| Float Shares | 47,157,467 |
| Forward Eps | -1.68 |
| Forward P E | -1.4583334 |
| Free Cashflow | -20,904,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 9 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.29101 |
| Held Percent Institutions | 0.17642 |
| Implied Shares Outstanding | 65,827,448 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,332,460,800 |
| Last Split Factor | 1:6 |
| Long Business Summary | Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia. |
| Long Name | Galectin Therapeutics Inc. |
| Market | us_market |
| Market Cap | 161,277,248 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1065415 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-19 |
| Net Income To Common | -30,974,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 160,948,110 |
| Number Of Analyst Opinions | 1 |
| Open | 2.31 |
| Operating Cashflow | -23,875,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Peg Ratio | -36.15 |
| Phone | 678 620 3186 |
| Prev Name | Galectin Therapeutics, Inc. |
| Previous Close | 2.26 |
| Price Hint | 4 |
| Price To Book | -1.2442864 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.207 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.19 |
| Regular Market Change Percent | 8.40708 |
| Regular Market Day High | 2.4882 |
| Regular Market Day Low | 2.29 |
| Regular Market Day Range | 2.29 - 2.4882 |
| Regular Market Open | 2.31 |
| Regular Market Previous Close | 2.26 |
| Regular Market Price | 2.45 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 540,426 |
| Return On Assets | -0.67805 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 65,827,448 |
| Shares Percent Shares Out | 0.1033 |
| Shares Short | 6,801,737 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 5,169,383 |
| Short Name | Galectin Therapeutics Inc. |
| Short Percent Of Float | 0.16209999 |
| Short Ratio | 21.73 |
| Source Interval | 15 |
| State | GA |
| Symbol | GALT |
| Target High Price | 11.0 |
| Target Low Price | 11.0 |
| Target Mean Price | 11.0 |
| Target Median Price | 11.0 |
| Total Cash | 17,720,000 |
| Total Cash Per Share | 0.269 |
| Total Debt | 137,719,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.48 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.95105 |
| Two Hundred Day Average Change | -1.50105 |
| Two Hundred Day Average Change Percent | -0.37991166 |
| Type Disp | Equity |
| Volume | 540,426 |
| Website | https://galectintherapeutics.com |
| Zip | 30,071 |